NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
21 Jul 2017

Kala Pharmaceuticals Announces Pricing of Initial Public Offering

Kala Pharmaceuticals, Inc. announced that is has priced its initial public offering of 6,000,000 shares.
10 Jul 2017

Prexton announces initiation of phase II clinical testing in Parkinson’s disease

Prexton Therapeutics (Prexton), today announces the launch of phase II clinical testing of its investigational drug candidate, Foliglurax, in Parkinson’s disease (PD).
05 Jul 2017

Matthew Gantz Appointed CEO of Oxthera

OxThera AB, today announced the appointment of Matthew Gantz as their new CEO.
30 Jun 2017

Babyscripts Raises $5.7 Million to Build the Market’s Most Robust, Clinically-Validated Virtual Care Women’s Health Platform

Babyscripts, announced today that it has raised $5.7 million in new funding.
19 Jun 2017

Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients

Takeda Pharma AG and TiGenix NV today announced that the Swiss Agency for Therapeutic Products has accepted for review the file on investigational compound Cx601 to treat complex perianal fistulas in patients with Crohn’s disease.
15 Jun 2017

TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn’s Disease and Ulcerative Colitis

TiGenix NV today announces partnerships with the largest patient advocacy groups focused on Crohn’s disease and ulcerative colitis. 
13 Jun 2017

TiGenix Launches Global Phase III Trial for Cx601

TiGenix NV today announces that it has hosted its first European investigator meeting, which formally launches the global pivotal phase III clinical trial for Cx601 for the treatment of complex perianal fistulas in patients with Crohn’s disease.
12 Jun 2017

TiGenix announces final equity payment for cardiac platform acquisition

TiGenix NV today announces a €5 million milestone payment in new TiGenix shares to Genetrix in relation to the cardiac platform acquisition that took place in July 2015. 
01 Jun 2017

EUR 20 million EIB loan facility under the InnovFin programme to support medical diagnostics innovation in Spain

The European Investment Bank is supporting the improvement of infectious diseases diagnostics through a EUR 20 million loan agreement signed today with STAT-Dx.
23 May 2017

Anaconda Biomed Secures 15 Million Euro in Series A Financing Led by Ysios Capital, Innogest Capital and Omega Funds.

Anaconda Biomed, announces it has closed a Series A financing of 15 million Euro.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка